2 SEQUENT share price target reports by brokerages below. See what is analyst's view on SEQUENT share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
With the API business gaining significant proportion over the last one year, SSL gets a strong earnings base over which the formulations business growth will continue to be built. The API business has further steam left and can continue to grow in high-teens to mid-20s, driven by an improved product/geography mix. Currently, about 57% of the API revenue comes from regulated markets which continue to improve as the company starts filing more products in the US. In addition to geography mix, pricing dynamics in the API space are also supportive. On the formulations front, the company is expecting growth, driven by approval of new registrations. The larger part of growth in formulations segment will be driven by monetization of the injectable pipeline in the US and other regulated markets which should begin FY21 onwards. The first injectable filing for the US markets will happen in FY21
On a rough cut basis, in FY19, Topline will see a steady rise wherein Topline is expected to touch Rs 1042 crs in FY19E. On the bottomline level we expect the company to record a PAT of Rs 50 crs in FY19E. Thus on a conservative basis, SeQuent should record a EPS of Rs 2.04 for FY19E. For FY20E and FY21E our expectation is that earnings traction for SeQuent would continue to be strong wherein we expect a EPS of Rs 3 and Rs 4.18 respectively.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.